A carregar...
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass
Receptor activator of NF-κB ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits, osteoclastogenesis. A neutralizing Ab against RANKL, denosumab, improves bone strength in osteoporosis. OPG also improves muscle strength in mouse models of Duchenne’s muscular dystrophy (mdx) and denervation...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6668701/ https://ncbi.nlm.nih.gov/pubmed/31120440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI125915 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|